cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.25934/pr00007558
title: Immunogenicity and Safety Study of Two Different Formulations of GlaxoSmithKline (GSK) Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine, Rotarix in Healthy Infants

description: The purpose of this study is to evaluate the immunogenicity, reactogenicity and safety of GSK Biologicals' HRV liquid vaccine compared to GSK Biologicals' HRV lyophilized vaccine when administered as a two-dose primary vaccination in healthy infants aged 6-10 weeks at dose one, with no previous history of rotavirus illness or vaccination. While the lyophilized formulation of the HRV vaccine was licensed in India in February 2008, this study is conducted to generate additional clinical data for the liquid formulation of the HRV vaccine in India, as recommended by New Drug Advisory Committee on Vaccines (NDAC-Vaccines) of Drug Controller General of India (DCGI).
DOI: 10.25934/pr00009139
title: Interventional, Open-label Study of Flexible Doses of Vortioxetine on Depressive Symptoms in Patients With Major Depressive Disorder and Early Dementia

description: This study evaluates the effectiveness of vortioxetine on depressive symptoms in patients with depression and early dementia
DOI: 10.25934/00000432
title: Randomised, Double-blind, Placebo Controlled, Cross-over Study Comparing the Effects of Both Single Dose and Repeated Dosing Treatment for 14 Days of Vestipitant or Vestipitant / Paroxetine Combination in an Enriched Population of Subjects With Tinnitus & Hearing Loss

description: Tinnitus associated to hearing loss is a high prevalent audiologic disorder with important unmet needs as far as therapy is concerned. The present study is exploring the possible beneficial effects on tinnitus loudness or annoyance of a combination drug treatment aimed to increase the local inhibitory activity of neural circuitries involved in sound perception and generation. Modest effects have been reported after 8-12 weeks treatment with antidepressants, including high dose paroxetine (up to 50 mg/day). Biologic data suggests that the combination of increase of extracellular serotonin using an SSRI and of blockade of NK1 receptors using a novel NK1 antagonist may lead to a reduced tinnitus and, possibly, improved hearing acuity. To this aim, two 14 day treatment conditions, i.e., SSRI paroxetine (20 mg/day) plus the NK1 antagonist vestipitant (25mg /day) or vestipitant alone (25 mg /day), will be compared to placebo in patients suffering from tinnitus previously selected for their capacity to reliably score the transient attenuation of tinnitus loudness produced by lidocaine infusion. Effects on principal endpoints will be collected within 4 hrs from last administration, when the plasma levels of vestipitant are calculated to be in the range associated to pharmacodynamic effects on VAS anxiety and qEEG (>30 ng/ml). PK, safety and tolerability of the paroxetine-vestipitant combination was addressed with preclinical and Phase I studies, showing no relevant issue. The cross-over study will require approximately 24 patients. Audiometry and computer-based Automated Psychoacoustics will be performed as instrumental endpoints to support subjective scores. A diary will be used at home to score tinnitus severity at home during the study.
DOI: 10.25934/00001098
title: Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' HPV-16/18 L1 AS04 Vaccine and Merck's Gardasil® Vaccine When Administered According to Alternative 2-dose Schedules in 9-14 Year Old Females

description: The purpose of this study is to evaluate the immunogenicity and the safety of Cervarix administered according to a 2-dose schedule at 0, 6 months compared to Gardasil, administered according to a 2-dose schedule at 0, 6 months or the standard 3-dose schedule of 0, 2, 6 months in 9-14 years old healthy females.
DOI: 10.25934/00002066
title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Assess the Efficacy and Safety of Lovaza for the Prevention of Recurrent, Symptomatic Atrial Fibrillation

description: The purpose of this study is to evaluate efficacy and safety of Omacor (omega-3-acid ethyl esters) in patients with recurrent, symptomatic atrial fibrillation.
DOI: 10.25934/00002164
title: U0289-404: An Evaluator Blinded, 8 Week, Split Face Study to Evaluate and Compare the Efficacy and Tolerability of MAXCLARITYII and MURAD in Subjects With Acne

description: One of the main success factors in acne therapy is user compliance with treatment, product cost, availability and ease of use. Poor compliance may translate into decreased efficacy (either not improving symptoms well enough or not improving symptoms fast enough), tolerability issues or adverse effects (eg, erythema, dryness, or peeling of the skin), a lack of understanding of the instructions for use, or product cost/availability. Whatever the reason, poor compliance translates to decreased efficacy and increased frustration on the part of the user. The current study will evaluate and compare the efficacy and tolerability of 2 over the counter, topical product lines for the treatment of acne: MAXCLARITY II Foam Cleanser (2.5% benzoyl peroxide [BPO]) plus Foam Treatment (2.5% BPO) and (0.5% Salicylic Acid) Toner Foam compared with MURAD Clarifying Cleanser (1.5% salicylic acid [SA]) plus Exfoliating Acne Treatment Gel (1% SA) and Skin Perfecting Lotion.
DOI: 10.25934/00004508.0
title: Available IPD datapackage for study 'A Randomized, Double-Blind, Placebo- and Active-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate Therapy'

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/00006078
title: An Escalating Dose, Randomized, Placebo-controlled, Incomplete-block, 2-period Cross-over Study to Assess the Dose Response for Topical Efficacy Via Airway Responsiveness to Adenosine-5'-Monophosphate (AMP) Challenge and the Dose Response for Systemic Activity Via 24h Plasma Cortisol Suppression and Thereby the Relative Therapeutic Index for Fluticasone Furoate (FF), Fluticasone Propionate (FP) and Budesonide (BUD) in Asthmatic Subjects

description: This is a randomized, placebo-controlled, 2-period crossover, escalating repeat dose study, aiming to investigate whether higher potency of different inhaled corticosteroid confers an improvement in the topical efficacy to systemic activity ratio in asthmatic subjects. It will compare the dose response for topical efficacy via airway responsiveness (to adenosine-5'-monophosphate [AMP] challenge), and the dose response for systemic activity via 24 hour plasma cortisol suppression, and thereby compare the relative therapeutic index, for the following inhaled corticosteroids: fluticasone furoate (FF), fluticasone propionate (FP) and budesonide (BUD). There will be a screening visit 4 - 42 days before the first dose of study treatment, and AMP challenge Provocative concentration 20 (PC20) of <=80 milligrams per milliliter (mg/mL) at screening visit 2 i.e. at 4 - 14 days before the first dose of study treatment. Subjects will be randomized to one of 5 or 12 treatment sequences, and will have one or two treatment periods, each comprising 5 consecutive 7-day phases of escalating doses of either FF, FP, BUD or placebo. There will be a 25- to 42-day washout period between treatment periods. The study duration for each subject will be approximately 13 or 24 weeks including the follow-up period.
DOI: 10.25934/pr00006023.0
title: Available IPD datapackage for study 'A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate Therapy'

description: The main purpose of this study is to evaluate the safety and effectiveness of the study drug known as baricitinib in participants with moderately to severely active rheumatoid arthritis who have had an inadequate response to methotrexate therapy.
DOI: 10.25934/pr00006879.0
title: Available IPD datapackage for study 'A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Subjects Assessed to be at Imminent Risk for Suicide'

description: The purpose of this study is to evaluate the efficacy of intranasal esketamine 84 milligram (mg) compared with intranasal placebo in addition to comprehensive standard of care in reducing the symptoms of Major Depressive Disorder (MDD), including suicidal ideation, in participants who are assessed to be at imminent risk for suicide, as measured by the change from baseline on the Montgomery-Asberg Depression Rating Scale (MADRS) total score at 24 hours post first dose.
DOI: 10.25934/pr00007888
title: Open-Label, Single-Arm, Multicenter, Pharmacokinetic, Safety, and Efficacy Study of Adjunctive Administration of Brivaracetam in Subjects From ≥1 Month to <16 Years Old With Epilepsy

description: Initial study in children with epilepsy to evaluate the pharmacokinetics, safety, tolerability and preliminary efficacy of adjunctive treatment with brivaracetam, and to develop dosing adaptations for future studies.
DOI: 10.25934/pr00008254
title: A Parallel Group, Double-Blind, Randomized, Placebo Controlled, Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Frequent Episodic Migraines

description: The purpose of this study is to assess ALD403 in the prevention of migraine headache in frequent episodic migraineurs.
DOI: 10.25934/pr00010944.0
title: Available datapackage for study 'Usage Tracking Test Data Set 10 - do not request'

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/00001235
title: Immunogenicity and Safety of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults With a Prior Episode of Herpes Zoster

description: The purpose of this study is to evaluate the immunogenicity and safety of GSK Biologicals' HZ/su vaccine in subjects' ≥ 50 years of age (YOA) who previously have had Herpes Zoster (HZ). The data collected will be compared with the data from subjects without HZ in other HZ/su trials.
DOI: 10.25934/pr00009419
title: An open label study to assess the 5.3.5.1.2 safety and efficacy of atorvastatin/amlodipine/perindopril fixed dose combination in adult patients, following four weeks of adequate treatment with atorvastatin, amlodipine and perindopril given concurrently (NP38275)

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.15468/dl.vcdzrn
title: Occurrence Download

description: A dataset containing 28 species occurrences available in GBIF matching the query:
{
 "and" : [
 "BasisOfRecord is Specimen",
 "TaxonKey is Notylia albida Klotzsch"
 ]
}

 The dataset includes 28 records from 13 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0005202-250227182430271/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.25934/00001118
title: Study ATG115317, a Comparison of Atorvastatin and Glimepiride Fixed Dose Combination and Atorvastatin and Glimepiride Loose Combination in the Treatment of Patients With Type 2 Diabetes Mellitus

description: The aim of this 20 week study is to show that glimepiride/atorvastatin fixed dose combination tablet is safe and as effective as atorvastatin + glimepiride combination taken as separate tablets, in improving glycaemic control (glycated haemoglobin, HbA1c) and cholesterol levels (Low-density lipoprotein, LDL) in diabetic subjects, who are inadequately controlled on a stable dose of metformin. Eight dose combinations will be included.
DOI: 10.25934/00001208
title: Open-label Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults Aged 50 Years or Older

description: The purpose of this study is to assess the safety and immunogenicity of the GSK Biologicals' HZ vaccine 1437173A administered on either a 0,2-; 0,6- or 0,12-month schedule in adults aged 50 years or above, as the immunogenicity of the HZ vaccine administered at intervals longer than two months is not known.
DOI: 10.25934/pr00008423
title: Multi-center, Open Label, Single Arm Study to Assess Efficacy, Safety, Bleeding Pattern and Pharmacokinetics of the Ultra Low Dose Levonorgestrel Intrauterine Contraceptive System (LCS) for a Maximum of 3 Years in Women 18 to 40 Years of Age

description: The purpose of this study is to assess the efficacy, safety, bleeding pattern of low dose LNG (12 mg/ 24 hrs), delivered locally by a new intrauterine contraceptive system suitable for use by women 18 to 40 years of age. In addition, pharmacokinetic assessments will be performed.
DOI: 10.25934/pr00010579
title: Phase 1, Randomized, Blinded, Placebo-Controlled, Single-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Dapirolizumab Pegol (BIIB133) in Healthy Japanese and Caucasian Study Participants

description: The primary objective of the study is to assess the safety and tolerability of a single intravenous (IV) dose of dapirolizumab pegol (DZP) in Japanese healthy study participants compared with those of Caucasian healthy study participants.The secondary objectives of the study are to assess the pharmacokinetic(s) (PK) of a single IV dose of DZP in Japanese and Caucasian healthy study participants, to evaluate ethnic sensitivity on the PK of DZP between body weight- and gender-matched Japanese and Caucasian healthy study participants and to evaluate the immunogenicity of a single IV dose of DZP in Japanese and Caucasian healthy study participants.
DOI: 10.25934/00005875.0
title: Available IPD datapackage for study 'A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Active-Referenced, Fixed-Dose Study Comparing the Efficacy and Safety of 2 Doses of Lu AA21004 in Acute Treatment of Adults With Major Depressive Disorder'

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/pr00010722
title: Usage Tracking Test Data Set 2 - do not request

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.15468/dl.vwsdxp
title: Occurrence Download

description: A dataset containing 51 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Country is Ecuador",
 "Geometry POLYGON((-111.33343 -6.72792,-47.66657 -6.72792,-47.66657 18.72792,-111.33343 18.72792,-111.33343 -6.72792))",
 "HasCoordinate is true",
 "HasGeospatialIssue is false",
 "OccurrenceStatus is Present",
 "PublishingOrg is one of (6441aff3-344f-486e-a4a2-f506c3bcb1ee, 90fd6680-349f-11d8-aa2d-b8a03c50a862, 8e1a97a0-3ca8-11d9-8439-b8a03c50a862, c54097e6-0972-4acb-b849-eaeba29c917d, 335880a0-e2e1-11dd-8102-b8a03c50a862, 87a78f75-b63e-4c3e-9ecf-7557e13f090e)",
 "TaxonKey is Astrocaryum standleyanum L.H.Bailey"
 ]
}

 The dataset includes 51 records from 7 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0005193-250227182400228/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.5281/zenodo.14961688
title: JinanHighPM2.5: Big data-driven 500m and 1h PM2.5 dataset for urban Jinan (2019-2021)

description: Welcome to our dataset published on Zenodo! We are delighted to share this meticulously prepared data product with you.

JinanHighPM2.5 is a high-quality PM2.5 concentration dataset generated using machine learning techniques to integrate multi-source big data such as mobile monitoring, micro-station measurements, and so on. This high spatiotemporal resolution dataset has a spatial resolution of ~500m and a temporal resolution of 1h, covering an area of 900km2 in Jinan (the urban area is included), Shandong Province, China from January 2019 to September 2021. The dataset has undergone rigorous processing and verification to ensure the accuracy and reliability of the data. Whether for researchers conducting in-depth studies or professionals using it for practical application analysis, this dataset can provide robust data support.

We hope that you will have a smooth and enjoyable experience when using this dataset for your scientific research work, achieve your desired research results, and continuously make new discoveries and breakthroughs on the path of exploring knowledge.   

If our work has been helpful to your research, project, or other related endeavors, we kindly request that you cite our article in your corresponding achievements. Your citation is not only an acknowledgment of our efforts but also contributes to promoting academic exchanges and development in the relevant field. Thank you again for your attention to and use of this dataset!



Li, T., Huang, X., Zhang, Q., Wang, X., Wang, X., Zhu, A., Wei, Z., Wang, X., Wang, H., Chen, J., Li, M., Wang, Q., and Wang, W. Machine learning-guided integration of fixed and mobile sensors for high resolution urban PM2.5 mapping. Npj Clim. Atmospheric Sci (2025). 


Thank you so much! Wishing you success in your research and a happy life!
DOI: 10.5281/zenodo.14961689
title: JinanHighPM2.5: Big data-driven 500m and 1h PM2.5 dataset for urban Jinan (2019-2021)

description: Welcome to our dataset published on Zenodo! We are delighted to share this meticulously prepared data product with you.

JinanHighPM2.5 is a high-quality PM2.5 concentration dataset generated using machine learning techniques to integrate multi-source big data such as mobile monitoring, micro-station measurements, and so on. This high spatiotemporal resolution dataset has a spatial resolution of ~500m and a temporal resolution of 1h, covering an area of 900km2 in Jinan (the urban area is included), Shandong Province, China from January 2019 to September 2021. The dataset has undergone rigorous processing and verification to ensure the accuracy and reliability of the data. Whether for researchers conducting in-depth studies or professionals using it for practical application analysis, this dataset can provide robust data support.

We hope that you will have a smooth and enjoyable experience when using this dataset for your scientific research work, achieve your desired research results, and continuously make new discoveries and breakthroughs on the path of exploring knowledge.   

If our work has been helpful to your research, project, or other related endeavors, we kindly request that you cite our article in your corresponding achievements. Your citation is not only an acknowledgment of our efforts but also contributes to promoting academic exchanges and development in the relevant field. Thank you again for your attention to and use of this dataset!



Li, T., Huang, X., Zhang, Q., Wang, X., Wang, X., Zhu, A., Wei, Z., Wang, X., Wang, H., Chen, J., Li, M., Wang, Q., and Wang, W. Machine learning-guided integration of fixed and mobile sensors for high resolution urban PM2.5 mapping. Npj Clim. Atmospheric Sci (2025). 


Thank you so much! Wishing you success in your research and a happy life!
DOI: 10.15468/dl.rd4fwt
title: Occurrence Download

description: A dataset containing 2457 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Country is United States of America",
 "Month is January",
 "TaxonKey is Sciurus niger Linnaeus, 1758",
 "Year 2024-2025"
 ]
}

 The dataset includes 2457 records from 3 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0005203-250227182430271/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.wsv7t9
title: Occurrence Download

description: A dataset containing 1306392 species occurrences available in GBIF matching the query:
{
 "DatasetKey" : [
 "is Données d'occurrences Espèces issues de l'inventaire des ZNIEFF"
 ]
}

 The dataset includes 1306392 records from 1 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0005190-250227182400228/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.keqrrw
title: Occurrence Download

description: A dataset containing 25207200 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Mammalia",
 "HasCoordinate is true",
 "HasGeospatialIssue is false",
 "OccurrenceStatus is Present",
 {
 "not" : {
 "BasisOfRecord" : [
 "is one of (Living Specimen)"
 ]
 }
 },
 {
 "or" : [
 "CoordinateUncertaintyInMeters is less than 10000",
 "CoordinateUncertaintyInMeters is null"
 ]
 },
 {
 "not" : {
 "License" : [
 "is one of (CC-BY-NC 4.0)"
 ]
 }
 }
 ]
}

 The dataset includes 25207200 records from 12521 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0005194-250227182430271/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.tfqu39
title: Occurrence Download

description: A dataset containing 258187 species occurrences available in GBIF matching the query:
{
 "and" : [
 {
 "or" : [
 "PublishingCountry is Colombia",
 {
 "and" : [
 "Country is Colombia",
 {
 "not" : {
 "Issue" : [
 "is Country coordinate mismatch"
 ]
 }
 }
 ]
 }
 ]
 },
 {
 "and" : [
 "StateProvince is one of (cundinamarca)",
 "TaxonKey is one of (Tracheophyta)"
 ]
 }
 ]
}

 The dataset includes 258187 records from 211 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0011926-240229165702484/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.